[go: up one dir, main page]

PE20081487A1 - DERIVADOS DE NICOTINAMIDA COMO INHIBIDORES DE 11ßHSD1 - Google Patents

DERIVADOS DE NICOTINAMIDA COMO INHIBIDORES DE 11ßHSD1

Info

Publication number
PE20081487A1
PE20081487A1 PE2007001517A PE2007001517A PE20081487A1 PE 20081487 A1 PE20081487 A1 PE 20081487A1 PE 2007001517 A PE2007001517 A PE 2007001517A PE 2007001517 A PE2007001517 A PE 2007001517A PE 20081487 A1 PE20081487 A1 PE 20081487A1
Authority
PE
Peru
Prior art keywords
alkyl
11ßhsd1
inhibitors
cyclohexylcarbamoil
pyridin
Prior art date
Application number
PE2007001517A
Other languages
English (en)
Inventor
William Maccoull
Martin Packer
Paul Robert Owen Whittmore
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20081487A1 publication Critical patent/PE20081487A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE NICOTINAMIDA DE FORMULA (I), EN DONDE Q ES UN ENLACE SIMPLE, -O-, -S- u -N(R15)-; R1 ES ALQUILO(C1-C6), ALQUENILO(C2-C6), CICLOALQUILO(C3-C7), ENTRE OTROS; R2 ES CICLOALQUIL(C3-C7)(CH2)m- Y POLICICLOALQUIL(C6-C12)(CH2)m-, OPCIONALMENTE SUSTITUIDOS, EN DONDE m ES DE 0 A 2; R3 ES H, ALQUILO(C1-C4), ENTRE OTROS; O R2 Y R3 JUNTOS CON EL N AL QUE ESTAN UNIDOS FORMAN UN MONOCICLO SATURADO DE 5 A 6 MIEMBROS CON UN HETEROATOMO DE N, O Y S OPCIONALMENTE SUSTITUIDOS; R4 SON INDEPENDIENTEMENTE HALO, ALQUILO(C1-C2), CIANO, ALCOXI(C1-C2) Y TRIFLUOROMETILO; p ES DE 0 A 2; X ES O, S u -N(R12)-; Y ES UN CICLOALALCDIILO(C3-C7), HETEROCICLIO, ENTRE OTROS. SON SELECCIONADOS: ACIDO 2-[(3R)-1-[5-(CICLOHEXILCARBAMOIL)-6-PROPILSULFANIL-PIRIDIN-2-IL]-3-PIPERIDIL]ACETICO, ACIDO 3-[5-CICLOHEXILCARBAMOIL)-6-PROPILSULFANIL-PIRIDIN-2-IL]SULFANILBENZOICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA 11-ß-HIDROXIESTEROIDE DESHIDROGENASA DE TIPO 1 (11ßHSD1), SIENDO UTIL EN EL TRATAMIENTO DEL SINDROME METABOLICO, DIABETES TIPO 2, OBESIDAD Y ATEROSCLEROSIS
PE2007001517A 2006-11-03 2007-11-05 DERIVADOS DE NICOTINAMIDA COMO INHIBIDORES DE 11ßHSD1 PE20081487A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86430306P 2006-11-03 2006-11-03
US86424706P 2006-11-03 2006-11-03

Publications (1)

Publication Number Publication Date
PE20081487A1 true PE20081487A1 (es) 2009-01-11

Family

ID=39304797

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001517A PE20081487A1 (es) 2006-11-03 2007-11-05 DERIVADOS DE NICOTINAMIDA COMO INHIBIDORES DE 11ßHSD1

Country Status (30)

Country Link
US (3) US7964618B2 (es)
EP (2) EP2233480B1 (es)
JP (1) JP5165688B2 (es)
KR (1) KR101465275B1 (es)
CN (3) CN101787016B (es)
AR (1) AR063458A1 (es)
AT (1) ATE475649T1 (es)
AU (1) AU2007315955B2 (es)
BR (1) BRPI0717970C1 (es)
CA (1) CA2668006C (es)
CL (1) CL2007003176A1 (es)
CO (1) CO6321130A2 (es)
CY (1) CY1110813T1 (es)
DE (1) DE602007008137D1 (es)
DK (1) DK2086939T3 (es)
ES (2) ES2347491T3 (es)
HR (1) HRP20100522T1 (es)
IL (1) IL198231A0 (es)
MX (1) MX2009004707A (es)
NO (1) NO20091603L (es)
NZ (1) NZ576501A (es)
PE (1) PE20081487A1 (es)
PL (1) PL2086939T3 (es)
PT (1) PT2086939E (es)
RS (1) RS51451B (es)
RU (1) RU2451674C2 (es)
SI (1) SI2086939T1 (es)
TW (1) TW200827346A (es)
UY (1) UY30681A1 (es)
WO (1) WO2008053194A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4276280B2 (ja) 2005-11-21 2009-06-10 塩野義製薬株式会社 Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
TW200836719A (en) * 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
RU2455285C2 (ru) 2007-05-18 2012-07-10 Сионоги Энд Ко., Лтд. АЗОТСОДЕРЖАЩЕЕ ГЕТЕРОЦИКЛИЧЕСКОЕ ПРОИЗВОДНОЕ, ОБЛАДАЮЩЕЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ 11β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ ТИПА 1
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2202228B1 (en) * 2007-10-15 2014-12-10 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
WO2009056881A1 (en) * 2007-10-29 2009-05-07 Astrazeneca Ab Chemical compounds 313
CA2713409A1 (en) * 2008-02-04 2009-08-13 Astrazeneca Ab Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid
CA2719936A1 (en) * 2008-04-22 2009-10-29 Astrazeneca Ab Substituted pyrimidin-5-carboxamides 281
EP2243479A3 (en) 2009-04-20 2011-01-19 Abbott Laboratories Novel amide and amidine derivates and uses thereof
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
UY32954A (es) * 2009-10-20 2011-05-31 Astrazeneca Ab PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.
CN102712607B (zh) * 2009-11-24 2016-06-22 阿勒根公司 作为具有治疗效用的受体调节剂的化合物
WO2011068927A2 (en) * 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR20110123657A (ko) * 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CA2809675A1 (en) 2010-09-23 2012-03-29 Shuang Chen Monohydrate of an azaadamantane derivative
US8471027B2 (en) * 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
JP5697800B2 (ja) * 2011-07-21 2015-04-08 シュエンジュウ・ファーマ・カンパニー・リミテッド 複素環置換ピリミジン化合物
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN102659657B (zh) * 2012-04-24 2014-08-06 徐州医学院 一种蛋白酶抑制剂pf429242的合成方法
IN2014DN09347A (es) 2012-06-20 2015-07-17 Hoffmann La Roche
PE20142448A1 (es) 2012-06-20 2015-01-28 Hoffmann La Roche Compuestos de n-alquiltriazol como antagonistas de lpar
EP3821892A1 (en) 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
GB202216324D0 (en) * 2022-11-02 2022-12-14 Cerevance Ltd Novel compounds
GB202408335D0 (en) 2024-06-11 2024-07-24 Astrazeneca Ab Therapies for wound treatment

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR66581B (es) 1978-02-21 1981-03-27 Delalande Sa
CA1307786C (en) 1984-12-14 1992-09-22 Keiichi Yokoyama Quinazoline derivatives and antihypertensive preparations containing same as effective components
CN102584799A (zh) 1999-09-16 2012-07-18 田边三菱制药株式会社 含氮的6-员芳香环化合物
FR2803592A1 (fr) * 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
WO2002034711A1 (en) 2000-10-20 2002-05-02 Biocryst Pharmaceuticals, Inc. Biaryl compounds as serine protease inhibitors
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
AU2003217046A1 (en) 2002-04-05 2003-10-27 The University Of Edinburgh Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
SE0300458D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
SE0300457D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
KR20050105488A (ko) 2003-02-26 2005-11-04 반유 세이야꾸 가부시끼가이샤 헤테로아릴카바모일벤젠 유도체
ATE482747T1 (de) 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
CA2534221A1 (en) 2003-08-07 2005-02-24 Merck & Co., Inc. Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
EA200600990A1 (ru) 2003-12-19 2006-10-27 Пфайзер Инк. Производные бензосульфониламинопиридин-2-ила и родственные соединения в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы 1 типа (11-бета-hsd-1) для лечения диабета и ожирения
DE602005009500D1 (de) 2004-02-24 2008-10-16 Glaxo Group Ltd Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
EP1761496A2 (en) * 2004-03-31 2007-03-14 Janssen Pharmaceutica N.V. Non-imidazole heterocyclic compounds as histamine h3-receptor ligands
CA2565843A1 (en) 2004-05-06 2005-11-17 Pfizer Inc. Novel compounds of proline and morpholine derivatives
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
PT1763517E (pt) 2004-06-28 2011-07-01 Hoffmann La Roche Derivados de pirimidina como inibidores 11beta-hsd1
CA2585735A1 (en) 2004-11-02 2006-05-11 Pfizer Inc. Novel compounds of substituted and unsubstituted adamantyl amides
EP1809290A2 (en) 2004-11-03 2007-07-25 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
MX2007008238A (es) 2005-01-05 2007-08-17 Abbott Lab Derivados de adamantilo como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1.
JP4880671B2 (ja) 2005-04-05 2012-02-22 エフ．ホフマン−ラ ロシュ アーゲー １Ｈ−ピラゾール４−カルボキシルアミドその製造方法および１１β−ヒドロキシステロイドデヒドロゲナーゼとしてのその使用
WO2006106054A1 (en) 2005-04-06 2006-10-12 F. Hoffmann-La Roche Ag Pyridine-3-carboxamide derivatives as cb1 inverse agonists
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
WO2006113261A2 (en) 2005-04-14 2006-10-26 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
JP2008542247A (ja) 2005-05-24 2008-11-27 アストラゼネカ アクチボラグ グルコキナーゼモジュレーターとしての２−フェニル置換イミダゾール［４，５ｂ］ピリジン／ピラジンおよびプリン誘導体
EP1894919B1 (en) 2005-06-07 2012-03-28 Shionogi & Co., Ltd. Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity
KR100970294B1 (ko) 2005-06-08 2010-07-15 니뽄 다바코 산교 가부시키가이샤 복소환 화합물
ES2334518T3 (es) 2005-06-16 2010-03-11 Pfizer, Inc. Derivados de n-(piridin-2-il)-sulfonamida.
EP2301935A1 (en) 2005-07-09 2011-03-30 AstraZeneca AB (Publ) Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
JP2009504621A (ja) 2005-08-09 2009-02-05 アストラゼネカ アクチボラグ 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体
US8680122B2 (en) 2005-11-01 2014-03-25 Janssen Pharmacetica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
JP4276280B2 (ja) 2005-11-21 2009-06-10 塩野義製薬株式会社 Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物
EA200870216A1 (ru) 2006-01-31 2009-02-27 Инсайт Корпорейшн Амидо соединения и их применение в качестве лекарственных средств
PL1999114T3 (pl) 2006-03-22 2015-12-31 Hoffmann La Roche Pirazole jako 11-Beta-HSD-1
KR20090014347A (ko) 2006-04-07 2009-02-10 하이 포인트 파마슈티칼스, 엘엘씨 11β-히드록시스테로이드 탈수소효소 타입 1 활성 화합물
CN101431994A (zh) 2006-04-27 2009-05-13 索尔瓦药物有限公司 CBx大麻素受体调节剂作为钾通道调节剂的用途
US20100022589A1 (en) 2006-07-27 2010-01-28 Mccoull William Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
RU2455285C2 (ru) 2007-05-18 2012-07-10 Сионоги Энд Ко., Лтд. АЗОТСОДЕРЖАЩЕЕ ГЕТЕРОЦИКЛИЧЕСКОЕ ПРОИЗВОДНОЕ, ОБЛАДАЮЩЕЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ 11β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ ТИПА 1
AU2008277783B2 (en) 2007-07-17 2012-09-20 F. Hoffmann-La Roche Ag Inhibitors of 11beta-hydroxysteroid dehydrogenase
CA2703781A1 (en) 2007-11-06 2009-05-14 Astrazeneca Ab 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465
CA2713409A1 (en) 2008-02-04 2009-08-13 Astrazeneca Ab Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid
CA2719936A1 (en) 2008-04-22 2009-10-29 Astrazeneca Ab Substituted pyrimidin-5-carboxamides 281
EP2391607A1 (en) 2009-01-30 2011-12-07 AstraZeneca AB Novel process for preparing carboxy-containing pyrazoleamido compounds 597
UY32954A (es) * 2009-10-20 2011-05-31 Astrazeneca Ab PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.

Also Published As

Publication number Publication date
NZ576501A (en) 2011-03-31
CA2668006C (en) 2016-05-24
JP2010508338A (ja) 2010-03-18
WO2008053194A2 (en) 2008-05-08
KR101465275B1 (ko) 2014-11-27
CN101787016A (zh) 2010-07-28
HRP20100522T1 (hr) 2010-11-30
DK2086939T3 (da) 2010-10-11
US20090312372A1 (en) 2009-12-17
CN102603711A (zh) 2012-07-25
AU2007315955A1 (en) 2008-05-08
CN101573336B (zh) 2012-03-21
WO2008053194A3 (en) 2008-10-02
US8673938B2 (en) 2014-03-18
SI2086939T1 (sl) 2010-10-29
AR063458A1 (es) 2009-01-28
JP5165688B2 (ja) 2013-03-21
IL198231A0 (en) 2009-12-24
EP2086939B1 (en) 2010-07-28
ES2347491T3 (es) 2010-10-29
CO6321130A2 (es) 2011-09-20
CN101573336A (zh) 2009-11-04
CA2668006A1 (en) 2008-05-08
PL2086939T3 (pl) 2011-09-30
PT2086939E (pt) 2010-09-17
BRPI0717970A2 (pt) 2013-11-05
AU2007315955B2 (en) 2011-04-14
RU2009115830A (ru) 2010-12-10
UY30681A1 (es) 2008-07-03
BRPI0717970B1 (pt) 2019-10-22
KR20090075865A (ko) 2009-07-09
NO20091603L (no) 2009-05-28
US20080269288A1 (en) 2008-10-30
EP2086939A2 (en) 2009-08-12
US7964618B2 (en) 2011-06-21
ES2423206T3 (es) 2013-09-18
US20090306075A1 (en) 2009-12-10
DE602007008137D1 (en) 2010-09-09
CL2007003176A1 (es) 2008-07-25
BRPI0717970C1 (pt) 2021-05-25
MX2009004707A (es) 2009-05-15
TW200827346A (en) 2008-07-01
EP2233480A1 (en) 2010-09-29
RU2451674C2 (ru) 2012-05-27
CN101787016B (zh) 2013-08-28
BRPI0717970B8 (pt) 2020-12-01
RS51451B (sr) 2011-04-30
EP2233480B1 (en) 2013-05-29
CY1110813T1 (el) 2015-06-10
HK1135090A1 (en) 2010-05-28
ATE475649T1 (de) 2010-08-15
EP2086939B8 (en) 2011-06-22

Similar Documents

Publication Publication Date Title
PE20081487A1 (es) DERIVADOS DE NICOTINAMIDA COMO INHIBIDORES DE 11ßHSD1
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20050948A1 (es) Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
PE20081836A1 (es) Derivados de piperidina como inhibidores de la sintasa de acido graso
NO20091560L (no) Biaryleterureaforbindelser
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20091687A1 (es) Derivados de piridina o pirazina como inhibidores de cinasa-pi-3
PE20091816A1 (es) Inhibidores de bace
PE20121440A1 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos
PE20091425A1 (es) Derivados de aminotiazol
PE20090366A1 (es) Composicion de efecto herbicida
CO6460743A2 (es) Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica
PE20080362A1 (es) Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
PE20090333A1 (es) Oxazolidinonas sustituidas y su uso
PE20090362A1 (es) Derivados de piperidina/piperazina como moduladores de dgat
MY173930A (en) Crystalline solvates and complexes of (is)-1,5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
PE20121474A1 (es) Nuevos compuestos de espiropiperidina
PE20090820A1 (es) Derivados de piperidina/piperazina
PE20110136A1 (es) Compuestos organicos
PE20090226A1 (es) PIRROLIDINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa Y SU PREPARACION
RU2008142600A (ru) Органическое соединение
PE20071326A1 (es) Inhibidores de la polimerasa viral
WO2009127948A8 (en) 4- [3- (aryloxy) benzylidene] -3-methyl piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
PE20071251A1 (es) Derivados de benzo-heteroaril sulfamida para el tratamiento del dolor

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed